ReviewFrontiers in immunology2026
Complement system in kidney transplantation: from innate immune surveillance to a therapeutic and genetic engineering target.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney transplantation remains the most effective treatment for end-stage kidney disease; however, long-term graft survival is constrained by rejection and chronic graft injury, and donor shortages continue to drive interest in xenotransplantation. The complement system is increasingly recognized both as a terminal effector of antibody-mediated injury and as a regulatory network linking antibody responses, endothelial activation, ischemia-reperfusion injury, coagulation, and innate immune cell responses. In this review, we compare the role of complement in allogeneic and xenogeneic kidney transplantation and provide an overview of emerging therapeutic strategies. In allogeneic transplantation, donor-specific anti-HLA and anti-ABO blood group antibodies activate complement, particularly via the classical pathway, and contribute to antibody-mediated rejection. Although C4d deposition is a key marker of complement activation, its clinical significance depends on the presence of microvascular inflammation, endothelial injury, and other immune mechanisms. Complement-binding donor-specific antibodies may improve risk stratification, whereas the clinical benefits of inhibiting C5, C3, and upstream complement in chronic active antibody-mediated rejection remain uncertain. In xenotransplantation, α-Gal and non-Gal antigens, their corresponding natural antibodies, complement activation via the classical, lectin, and alternative pathways, and interspecies incompatibilities in complement regulation collectively promote vascular endothelial injury and thromboinflammation. Multiplex genetic modification of donor pigs, including deletion of major carbohydrate antigens and expression of human complement and coagulation regulatory proteins, has substantially mitigated hyperacute rejection. However, achieving durable xenograft survival requires effective control of macrophages, natural killer cells, neutrophils, and their interactions with the graft endothelium. Therefore, integrated strategies combining genetic complement regulation, pharmacological complement inhibition, coagulation regulation, and innate immune modulation may be essential for preventing chronic allograft injury and improving long-term kidney xenograft survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.